GlassScriptPhysician profile
Elias Hsu
NPI 1902077332
$23,294.49
in general payments reported to CMS, 2019-2025
55 companies · $3,245 in 2025
The $3,245 reported for 2025 was more than what 87% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $3,057 · 2021: $1,652 · 2022: $1,754 · 2023: $1,655 · 2024: $1,807 · 2025: $3,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,623 · Consulting Fee: $955 · Education: $99.99 · Travel and Lodging: $28.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,623.43 |
| Consulting Fee | $955.00 |
| Education | $99.99 |
| Travel and Lodging | $28.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $12,126.95 | 2019-2023 | Myrbetriq |
| Medtronic, INC. | $2,048.67 | 2021-2025 | Interstim, Nuro |
| Boston Scientific Corporation | $1,100.50 | 2022-2025 | Upsylon, Lynx System, Capio Rp |
| Abbvie INC. | $769.75 | 2019-2024 | |
| Janssen Biotech, INC. | $632.37 | 2022-2025 | Erleada, Rybrevant, Carvykti |
| Coloplast Corp | $581.34 | 2021-2025 | Altis |
| Sumitomo Pharma America, INC. | $445.32 | 2023-2024 | Orgovyx, Gemtesa |
| Axonics, INC. | $430.96 | 2020-2024 | Bulkamid, Axonics |
| Allergan, INC. | $361.62 | 2019-2022 | |
| Progenics Pharmaceuticals, INC. | $348.48 | 2021-2025 | Pylarify |
| Bayer Healthcare Pharmaceuticals INC. | $326.21 | 2019-2023 | |
| Amgen INC. | $309.96 | 2019-2023 | Xgeva |
| Pfizer INC. | $306.09 | 2019-2024 | |
| Myovant Sciences INC. | $302.14 | 2021-2022 | |
| Telix Pharmaceuticals | $238.16 | 2022-2024 | Illuccix |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elias Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.